López-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, Sanjuán G, Suzuki Y, Ortega L, Blanco J, Egido J, Gómez-Guerrero C (2006). “Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis”. Arterioscler. Thromb. Vasc. Biol.26 (8): 1864–70. doi:10.1161/01.ATV.0000229659.94020.53. PMID16741149.
Feltenstein MW, Schühly W, Warnick JE, Fischer NH, Sufka KJ (2004). “Anti-inflammatory and anti-hyperalgesic effects of sesquiterpene lactones from Magnolia and Bear's foot”. Pharmacol. Biochem. Behav.79 (2): 299–302. doi:10.1016/j.pbb.2004.08.008. PMID15501305.
García-Piñeres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL, Merfort I (2001). “Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones”. J. Biol. Chem.276 (43): 39713-39720. doi:10.1074/jbc.M101985200. PMID11500489.
Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM (2001). “The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase”. Chem. Biol.8 (8): 759-766. doi:10.1016/S1074-5521(01)00049-7. PMID11514225.
Zunino SJ, Ducore JM, Storms DH (2007). “Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells”. Cancer lett.254 (1): 119–27. doi:10.1016/j.canlet.2007.03.002. PMID17470383.
Guzman ML, Jordan CT (2005). “Feverfew: weeding out the root of leukaemia”. Expert Opin. Biol> Ther.5 (9): 1147–52. doi:10.1517/14712598.5.9.1147. PMID16120045.
Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM (4 2005). “Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells”. Mol. Cancer Ther.4 (4): 587-594. doi:10.1158/1535-7163.MCT-04-0215. PMID15827332.
Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, Sweeney CJ (2010). “A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species”. Int. J. Cancer.. doi:10.1002/ijc.25587. PMID20669221.
Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA (2009). “Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1)”. Bioorg. Med. Chem. Lett.19 (15): 4346-4349. doi:10.1016/j.bmcl.2009.05.092. PMID19505822.
Miglietta A, Bozzo F, Gabriel L, Bocca C (2004). “Microtubule-interfering activity of parthenolide”. Chem. Biol. Interact.149 (2-3): 165–73. doi:10.1016/j.cbi.2004.07.005. PMID15501437.
Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J (2004). “Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity”. J. Bone Miner. Res.19 (11): 1905–16. doi:10.1359/JBMR.040919. PMID15476591.
T. R. Govindachari, B. S. Joshi and V. N. Kamat (1965). “Structure of parthenolide”. Tetrahedron21 (6): 1509-1519. doi:10.1016/S0040-4020(01)98314-0.
A. S. Bawdekar, G. R. Kelkar and S. C. Bhattacharyya (1966). “Terpenoids LXXXIX absolute configuration of parthenolide”. Tetrahedron Lett.7 (11): 1225-1227. doi:10.1016/S0040-4039(00)72397-5.
Andrew Quick and Donald Rogers (1976). “Crystal and molecular structure of parthenolide [4,5-epoxygermacra-1(10),11(13)-dien-12,6-olactone]”. J. Chem. Soc., Perkin Trans. 2: 465-469. doi:10.1039/P29760000465.
López-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, Sanjuán G, Suzuki Y, Ortega L, Blanco J, Egido J, Gómez-Guerrero C (2006). “Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis”. Arterioscler. Thromb. Vasc. Biol.26 (8): 1864–70. doi:10.1161/01.ATV.0000229659.94020.53. PMID16741149.
Feltenstein MW, Schühly W, Warnick JE, Fischer NH, Sufka KJ (2004). “Anti-inflammatory and anti-hyperalgesic effects of sesquiterpene lactones from Magnolia and Bear's foot”. Pharmacol. Biochem. Behav.79 (2): 299–302. doi:10.1016/j.pbb.2004.08.008. PMID15501305.
García-Piñeres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL, Merfort I (2001). “Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones”. J. Biol. Chem.276 (43): 39713-39720. doi:10.1074/jbc.M101985200. PMID11500489.
Hehner SP, Hofmann TG, Dröge W, Schmitz ML (1999). “The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex”. J. Immunol.163 (10): 5617-5623. PMID10553091.
Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM (2001). “The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase”. Chem. Biol.8 (8): 759-766. doi:10.1016/S1074-5521(01)00049-7. PMID11514225.
Zunino SJ, Ducore JM, Storms DH (2007). “Parthenolide induces significant apoptosis and production of reactive oxygen species in high-risk pre-B leukemia cells”. Cancer lett.254 (1): 119–27. doi:10.1016/j.canlet.2007.03.002. PMID17470383.
Guzman ML, Jordan CT (2005). “Feverfew: weeding out the root of leukaemia”. Expert Opin. Biol> Ther.5 (9): 1147–52. doi:10.1517/14712598.5.9.1147. PMID16120045.
Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM (4 2005). “Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells”. Mol. Cancer Ther.4 (4): 587-594. doi:10.1158/1535-7163.MCT-04-0215. PMID15827332.
Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, Sweeney CJ (2010). “A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-kappaB and generating reactive oxygen species”. Int. J. Cancer.. doi:10.1002/ijc.25587. PMID20669221.
Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA (2009). “Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1)”. Bioorg. Med. Chem. Lett.19 (15): 4346-4349. doi:10.1016/j.bmcl.2009.05.092. PMID19505822.
Miglietta A, Bozzo F, Gabriel L, Bocca C (2004). “Microtubule-interfering activity of parthenolide”. Chem. Biol. Interact.149 (2-3): 165–73. doi:10.1016/j.cbi.2004.07.005. PMID15501437.
Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J (2004). “Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity”. J. Bone Miner. Res.19 (11): 1905–16. doi:10.1359/JBMR.040919. PMID15476591.